# US 2022/0033399 A1 · Pyrrolopyridine-aniline compounds for treatment of dermal disorders

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0033399 A1
- Document ID: US20220033399A1
- Status: Published application
- Kind: A1
- Application number: 17/399,661
- Filed: 2021-08-11
- Published: 2022-02-03
- Earliest claimed: 2017-05-19
- Assignees: Nflection Therapeutics, Inc.
- Applicants: Nflection Therapeutics, Inc.
- Inventors: John Kincaid; Matthew Duncton
- Web page: https://patentgrep.com/patent/US20220033399A1

## CPC

- A61K 31/437: the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
- C07D 471/04: Ortho-condensed systems
- A61P 35/00: Antineoplastic agents
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

Provided herein are compounds, pharmaceutical compositions comprising the compounds, methods of preparing the compounds, and methods of using the compounds and compositions in treating diseases or disorders in a subject where the subject is in need of an inhibitor of MEK where the compound is according to Formula (I): wherein X1, R1, R2, R2a, R3, R3a, and R3b are as described herein.

## Claims

### Claim at position 1

1-58. (canceled)

### Claim at position 2

59-67. (canceled)

### Claim 68

A method of treating a MEK-inhibitor responsive disorder, MEK-inhibitor responsive dermal disorder, MEK-mediated disorder, or a MEK-mediated dermal disorder comprising administering to a subject in need thereof, a therapeutically effective amount of a compound of Formula (I):
or an N-oxide, a stereoisomer, mixture of stereoisomers, and/or a pharmaceutically acceptable salt thereof,
wherein:
R1 is —OR4, —NR5R5a, or an N-linked heterocycloalkyl wherein the N-linked heterocycloalkyl is optionally substituted with one or two R10;
R2a is halo or C1-C6 alkyl;
R2 is —S—C1-C6 alkyl, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, or halo;
X1 is C1-C6 alkyl;
R3, R3a, and R3b are independently hydrogen, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, —S—C1-C6 alkyl, halo, C1-C6 alkoxy, C3-C8-cycloalkyloxy, heterocycloalkyloxy, heteroaryloxy, or phenoxy wherein each phenyl and heteroaryl is independently optionally substituted with 1, 2, or 3 R6;
R4 is C1-C6 alkyl, C3-C8 cycloalkyl, C3-C8 cycloalkylalkyl, C1-C6 hydroxyalkyl, or C1-C6 alkoxyalkyl;
R5 is hydrogen, C1-C6 alkyl optionally substituted with one heterocycloalkyl, C3-C8 cycloalkyl, C3-C8 cycloalkyl-C1-C6-alkyl-, C1-C6 hydroxyalkyl, C1-C6 alkoxy-C1-C6-alkyl, or —OR5b;
R5a is hydrogen or C1-C6 alkyl;
R5b is hydrogen, C1-C6 alkyl, C3-C8 cycloalkyl, C3-C8 cycloalkyl-C1-C6-alkyl, C1-C6 hydroxyalkyl, or C1-C6 alkoxy-C1-C6-alkyl;
each R6 is independently selected from the group consisting of carboxy, C1-C6-alkoxycarbonyl, C1-C6-alkyl, C1-C6-haloalkyl, C1-C6-alkoxy-C1-C6-alkyl, C3-C8 cycloalkyl, heterocycloalkyl, —OC(O)R7, —OS(O)2R7, —O—C1-C6-haloalkyl, C3-C8 cycloalkyloxy, heterocycloalkyloxy, aryloxy, heteroaryloxy, amino, C1-C6-alkylamino, di-C1-C6-alkylamino, —NR8aS(O)2R8, —NR8aC(O)R8, —S(O)2R8, —S(O)2NRIaRg, —C(O)R8, —C(O)NR8aR8, and —C1-C6-alkylene-R6a;
each R6a is independently selected from the group consisting of C3-C8 cycloalkyl, heterocycloalkyl, —NH2, —NH(C1-C6-alkyl), —N(C1-C6-alkyl)2, —NR9aS(O)2R9, —NR9aC(O)R9, —S(O)2R9, —S(O)2NR9aR9, —C(O)R9, and —C(O)NR9aR9;
each R7 is independently selected from the group consisting of amino, C1-C6-alkylamino, di-C1-C6-alkylamino, C1-C6 alkyl, C3-C8 cycloalkyl, C1-C6-alkoxy, heterocycloalkyl, aryl, and heteroaryl;
each R8a and R9a is independently H or C1-C6 alkyl;
each R8 and R9 is independently C1-C6 alkyl, aryl, heteroaryl, C3-C8 cycloalkyl, or heterocycloalkyl; and
each R10 is independently hydrogen, halo, hydroxy, oxo, C1-C6 alkyl, C1-C6 hydroxyalkyl, C1-C6 haloalkyl, amino-C1-C6-alkyl, C1-C6-alkylamino-C1-C6-alkyl, di-C1-C6-alkylamino-C1-C6-alkyl, C1-C6-alkoxy, C3-C8 cycloalkyl, heterocycloalkyl, or heteroaryl.

### Claim 69 (depends on 68)

The method of claim 68, wherein the MEK-inhibitor responsive dermal disorder or a MEK-mediated dermal disorder is selected from the group consisting of a dermal rasopathy, a neurofibromatosis type 1, a cutaneous neurofibroma, a subdermal neurofibroma, and a superficial plexiform neurofibroma.

### Claim 70 (depends on 69)

The method of claim 69, wherein the dermal rasopathy is selected from the group consisting of psoriasis, keratocanthoma (KA), hyperkeratosis, papilloma, Noonan syndrome (NS), cardiofaciocutaneous syndrome (CFC), Costello syndrome (faciocutaneoskeletal syndrome or FCS syndrome), oculoectodermal syndrome, cafe au lait spots, pyogenic granuloma, sebaceous gland hyperplasia, cutaneous neurofibromas, seborrheic keratosis, sebaceous hyperplasia, seborrheic keratosis, and Multiple lentigines syndrome (formerly called Leopard syndrome).

### Claim 71 (depends on 68)

The method of claim 68, wherein the compound is administered topically, subcutaneously, transdermally, intradermally, or intralesionally.

### Claim 72 (depends on 68)

The method of claim 68, wherein X1 is —CH3.

### Claim 73 (depends on 68)

The method of claim 68, wherein R3 and R3b are each hydrogen and R3a is C1-C6 alkyl, halo, or C1-C6 alkoxy.

### Claim 74 (depends on 68)

The method of claim 68, wherein R3 and R3b are each hydrogen and R3a is methyl, fluoro, or methoxy.

### Claim 75 (depends on 68)

The method of claim 68, wherein R3, R3a, and R3b are hydrogen.

### Claim 76 (depends on 68)

The method of claim 68, wherein R2 is —S—C1-C6 alkyl.

### Claim 77 (depends on 76)

The method of claim 76, wherein R2 is —SCH3.

### Claim 78 (depends on 68)

The method of claim 68, wherein R2 is C2-C6 alkynyl.

### Claim 79 (depends on 78)

The method of claim 78, wherein R2 is C2-C3 alkynyl.

### Claim 80 (depends on 68)

The method of claim 68, wherein R2 is halo.

### Claim 81 (depends on 80)

The method of claim 80, wherein R2 is iodo.

### Claim 82 (depends on 68)

The method of claim 68, wherein R2a is C1-C6 alkyl.

### Claim 83 (depends on 82)

The method of claim 82, wherein R2a is methyl.

### Claim 84 (depends on 68)

The method of claim 68, wherein R2a is halo.

### Claim 85 (depends on 84)

The method of claim 84, wherein R2a is fluoro.

### Claim 86 (depends on 68)

The method of claim 68, wherein R1 is —NR5R5a and R5 is C1-C6 hydroxyalkyl.

### Claim 87 (depends on 68)

The method of claim 68, wherein R1 is —NR5R5a and R5 is —OR5b.

### Claim 88 (depends on 87)

The method of claim 87, wherein R5b is C3-C8 cycloalkyl-C1-C6-alkyl.

### Claim 89 (depends on 87)

The method of claim 87, wherein R5b is cyclopropylmethyl.

### Claim 90 (depends on 87)

The method of claim 87, wherein R5b is C1-C6 hydroxyalkyl.

### Claim 91 (depends on 90)

The method of claim 90, wherein R5b is an unbranched C1-C6 hydroxyalkyl.

### Claim 92 (depends on 90)

The method of claim 90, wherein the C1-C6 alkyl in C1-C6 hydroxyalkyl is substituted with one hydroxy.

### Claim 93 (depends on 68)

The method of claim 68, wherein R1 is —NR5R5a and R5a is hydrogen.

### Claim 94 (depends on 68)

The method of claim 68, wherein R1 is —NH—O—CH2CH2OH.

### Claim 95 (depends on 68)

The method of claim 68, wherein R1 is —NH—O—CH2(cyclopropyl).

### Claim 96 (depends on 68)

The method of claim 68, wherein the compound is selected from the group consisting of:
or a stereoisomer, mixture of stereoisomers, and/or a pharmaceutically acceptable salt thereof

### Claim 97 (depends on 68)

The method of claim 68, wherein the compound is selected from the group consisting of:

### Claim 98 (depends on 1)

The method of claim 1, wherein the subject is a human.
